Korean Journal of Pediatrics 2009;52(1):93-98.
Published online January 15, 2009.
Outcome of patients with neuroblastoma aged less than 1 year at diagnosis
Jung Min Suh1, Sang Goo Lee1, Keon Hee Yoo1, Ki Woong Sung1, Hong Hoe Koo1, Ju Youn Kim1, Eun Joo Cho1, Suk Koo Lee2, Jhingook Kim3, Do Hoon Lim4
1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Pediatric Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
진단 시 1세 이하인 신경모세포종 환자의 치료성적
서정민1, 이상구1, 유건희1, 성기웅1, 구홍회1, 김주연1, 조은주1, 이석구2, 김진국3, 임도훈4
1성균관대학교 의과대학 삼성서울병원 소아청소년과
2성균관대학교 의과대학 삼성서울병원 소아외과
3성균관대학교 의과대학 삼성서울병원 흉부외과
4성균관대학교 의과대학 삼성서울병원 방사선종양학과
Correspondence: 
Ki Woong Sung, Email: kwsped@skku.edu
Abstract
Purpose
: The purpose of this study was to evaluate the clinical characteristics and outcomes of patients with neuroblastoma aged less than 1 year.
Methods
: From January 1997 to December 2007, 41 patients aged less than 1 year were diagnosed with neuroblastoma. Patients were divided into 3 risk groups according to the stage of the disease and N-myc amplification. Low-risk patients underwent surgery with (stage 2) or without (stage 1) short-term chemotherapy. Intermediate-risk patients underwent chemotherapy and surgery with or without local radiation therapy. High-risk patients underwent chemotherapy, surgery, radiation therapy, and high-dose chemotherapy/autologous stem cell rescue (HDCT/ASCR).
Results
: While tumor relapse occurred in only 1 patient, 7 patients died of treatment-related toxicities. Causes of treatment- related death included infection during conventional chemotherapy in 5 patients and acute myocarditis during HDCT/ASCR in 2 patients. The overall 5-year survival (¡¾standard error) and 5-year event-free survival (EFS) rates after diagnosis for all 41 patients were 82.8¡¾5.9% and 80.0¡¾6.3%, respectively, with a median follow-up of 58 (9-137) months. The 5-year EFS rates for low-risk, intermediate-risk, and high-risk patients were 100%, 68.4¡¾10.8%, and 66.7¡¾19.3%, respectively.
Conclusion
: Increased efforts to reduce infection-associated toxicity deaths during conventional chemotherapy are needed to further improve the survival of patients with neuroblastoma aged less than 1 year.
Key Words: Neuroblastoma, Prognosis


METRICS Graph View
  • 2,363 View
  • 15 Download


Close layer
prev next